Detection of Choroidal Neovascularization Using Optical Tissue Transparency.

Detection of Choroidal Neovascularization Using Optical Tissue Transparency.
复制标题

DOI:
10.1167/tvst.12.6.10
复制
发表时间:
2023-06-01
影响因子:
3
通讯作者:
Sun, Xu-Fang
Sun, Xu-Fang
中科院分区:
医学3区
文献类型:
--
作者:
Ma, Xiao-Hong;Feng, Wen-Yang;Xiao, Ke;Zhong, Zheng;Fei, Peng;Zhao, Yin;Sun, Xu-Fang

文献摘要

参考文献

相似文献

光学组织透明度(OTT)提供了可视化整个组织块的工具。本研究旨在探讨OTT结合光片荧光显微镜(LSFM)检测脉络膜新生血管(CNV)病变的潜在价值。采用LSFM OCT、石蜡切片苏木精-伊红(H&E)染色、脉络膜平铺免疫荧光、光学相干断层血管成像(OCTA)等方法获得CNV图像。确定变化率为(第1周数据-第2周数据)/第1周数据×100%。最后,我们将从OTT获得的变化率与LSFM和其他方法进行了比较。我们发现,结合LSFM的OTT可以实现整个CNV的三维可视化。结果表明,激光光凝后1~2周,OTT组、H&E染色组、脉络膜平面组、OCTA组、血管直径指数(OCTA)组、OCTA组、OCTA组、LSFM的OTT将继续是调查人员检测更多关于CNV的可视化和量化信息的宝贵资源。带有LSFM的OTT现在可以作为检测小鼠CNV的工具,未来可能会进行人类临床试验。
Optical tissue transparency (OTT) provides a tool for visualizing the entire tissue block. This study provides insights into the potential value of OTT with light-sheet fluorescence microscopy (LSFM) in detecting choroidal neovascularization (CNV) lesions. OTT with LSFM, hematoxylin and eosin (H&E) staining of paraffin sections, choroidal flatmount immunofluorescence, and optical coherence tomography angiography (OCTA) were used to obtain images of CNV. We determined the rate of change as (Data of week 1 – Data of week 2)/Data of week 1 × 100%. Finally, we compared the rate of change acquired from OTT with LSFM and the other methodologies. We found that OTT with LSFM can realize three-dimensional (3D) visualizations of the entire CNV. The results showed that the decline in the rate of change from week 1 to week 2 after laser photocoagulation was 33.05% with OTT, 53.01% with H&E staining, 48.11% with choroidal flatmount, 24.06% with OCTA (B-scan), 18.08% with OCTA (en face), 10.98% with OCTA (3D reconstruction), and 7.74% with OCTA (vessel diameter index). OTT with LSFM will continue to be an invaluable resource for investigators to detect more visualized and quantified information regarding CNV. OTT with LSFM now serves as a tool for detecting CNV in mice, and it may undergo human clinical trials in the future.
DOI: 10.1016/j.jtos.2020.04.009
发表时间: 2020-07
期刊: The ocular surface
影响因子: --
作者:
Yang Y;Li G;Chen L
通讯作者: Chen L
DOI: 10.1371/journal.pone.0201958
发表时间: 2018
期刊: PloS one
影响因子: 3.7
作者:
Nakagawa K;Yamada H;Mori H;Toyama K;Takahashi K
通讯作者: Takahashi K
DOI: 10.1364/oe.20.004710
发表时间: 2012-02-13
期刊: Optics express
影响因子: 3.8
作者:
Jia Y;Tan O;Tokayer J;Potsaid B;Wang Y;Liu JJ;Kraus MF;Subhash H;Fujimoto JG;Hornegger J;Huang D
通讯作者: Huang D
DOI: 10.1186/s12575-021-00159-3
发表时间: 2021-11-11
影响因子: 6.4
作者:
Kumegawa S;Yamada G;Hashimoto D;Hirashima T;Kajimoto M;Isono K;Fujimoto K;Suzuki K;Uemura K;Ema M;Asamura S
通讯作者: Asamura S
DOI: 10.3791/61595
发表时间: 2021-03-01
影响因子: 1.2
作者:
Nazari, Hossein;Ivannikov, Maxim;Motamedi, Massoud
通讯作者: Motamedi, Massoud